Citation
- Authors: Guerard, M., Robin, T., Perron, P., Hatat, A. S., David-Boudet, L., Vanwonterghem, L., Busser, B., Coll, J. L., Lantuejoul, S., Eymin, B., Hurbin, A., Gazzeri, S.
- Year: 2018
- Journal: Cancer Lett 420 146-155
- Applications: in vitro / DNA, siRNA / jetPEI, jetPRIME
- Cell types:
- Name: A549
Description: Human lung carcinoma cells, type II pneumocytes
Known as: A-549 - Name: H322
- Name: H358
Description: Human bronchioalveolar carcinoma; non-small cell lung carcinoma cells - Name: H441
Description: Human lung papillary adenocarcinoma
- Name: A549
Abstract
Many Receptor Tyrosine Kinases translocate from the cell surface to the nucleus in normal and pathological conditions, including cancer. Here we report the nuclear expression of insulin-like growth factor-1 receptor (IGF1R) in primary human lung tumours. Using lung cancer cell lines and lung tumour xenografts, we demonstrate that the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib induces the nuclear accumulation of IGF1R in mucinous lung adenocarcinoma by a mechanism involving the intracellular re-localization of the growth factor amphiregulin. Amphiregulin allows the binding of IGF1R to importin-beta1 and promotes its nuclear transport. The nuclear accumulation of IGF1R by amphiregulin induces cell cycle arrest through p21(WAF1/CIP1) upregulation, and prevents the induction of apoptosis in response to gefitinib. These results identify amphiregulin as the first nuclear localization signal-containing protein that interacts with IGF1R and allows its nuclear translocation. Furthermore they indicate that nuclear expression of IGF1R contributes to EGFR-TKI resistance in lung cancer.